Ophthalmology company Nicox SA (Euronext Growth Paris:ALCOX) announced on Tuesday that its Japanese partner Kowa Company Ltd has initiated a Phase 3 safety clinical trial of NCX 470 in Japan for the treatment of ocular hypertension.
The trial launch triggers a EUR2m milestone payment to Nicox under the February 2024 licensing agreement.
Kowa is fully responsible for financing and managing the development of NCX 470 in Japan.
Only one additional confirmatory Phase 3 trial, expected to begin shortly, along with the safety trial, is required for submission for marketing approval in Japan.
NCX 470, also known as K-911, is a novel ophthalmic candidate aimed at addressing ocular hypertension.
The enrolment of the first patient marks a key milestone in the collaborative development programme between Nicox and Kowa.
Relay Therapeutics wins FDA breakthrough status for zovegalisib in breast cancer treatment
DATROWAY receives US priority review for first-line metastatic triple negative breast cancer
Valneva and Instituto Butantan launch pilot chikungunya vaccination campaign in Brazil
Lupin launches Dasatinib tablets in US market
WuXi Biologics enters into licence and research service agreement with Vertex Pharmaceuticals
Natera submits Signatera CDx PMA to FDA for bladder cancer use
Pharming receives FDA complete response letter for paediatric Joenja application
Astrazeneca Imfinzi perioperative regimen gains positive EU CHMP opinion in early gastric cancer
I Peace generates human iPS cells from NKT cells and offers them for research use
Trace Biosciences' IND application for nerve-specific imaging agent approved by FDA
Frontage expands early phase clinical research capabilities across US and China
AstraZeneca agrees obesity and type 2 diabetes collaboration with CSPC
Ascletis Pharma Inc reports topline results from Phase III open-label study of denifanstat
Innovative Molecules GmbH completes Phase 1 clinical development programme for adibelivir
MicuRx Pharmaceuticals' IND application for MRX-5 cleared by FDA